IP Library › Granted Patent US 7,345,175
Granted Patent B2
US 7,345,175 · App. 11/448,293 · Granted Mar 18, 2008

Biphenyl derivatives

Assignee: Theravance, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,345,175
App. No.
11/448,293
Granted
Mar 18, 2008
Kind
B2
Abstract

This invention provides biphenyl derivatives of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , W, a, b and c are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The biphenyl derivatives of this invention possess both β 2 adrenergic receptor agonist and muscarinic receptor antagonist activity and therefore, such biphenyl derivatives are useful for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

Claims (22)

1. A compound of the formula:

wherein

o is an integer from 2 to 7;

p is an integer from 1 to 6; provided that o+p is an integer from 3 to 8;

the phen-1,4-ylene group is optionally substituted with from 1 to 4 substituents independently selected from halo, (1-4C)alkyl, (1-4C)alkoxy, —S-(1-4C)alkyl, —S(O)-(1-4C)alkyl, —S(O) 2 -(1-4C)alkyl, —C(O)O(1-4C)alkyl, carboxy, cyano, hydroxy, nitro, trifluoromethyl and trifluoromethoxy;

or a pharmaceutically acceptable salt or solvate or stereoisomer thereof.

2. The compound of claim 1 , wherein o is 2 or 3.

3. The compound of claim 1 , wherein o is 2.

4. The compound of claim 1 , wherein p is 1 or 2.

5. The compound of claim 1 , wherein p is 1.

6. The compound of claim 1 , wherein o is 2 and p is 1.

7. The compound of claim 1 , wherein the phen-1,4-ylene group has one substituent.

8. The compound of claim 1 , wherein the phen-1,4-ylene group has two substituents.

9. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is halo.

10. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is chloro.

11. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is (1-4C)alkoxy.

12. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is methoxy.

13. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is (1-4C)alkyl.

14. The compound of claim 1 , wherein the phen-1,4-ylene group is substituted with from 1 to 4 substituents and at least one of the substituents is methyl.

15. The compound of claim 1 , wherein the compound has the (R) configuration at the carbon atom of the group —CH(OH)—.

16. The compound of claim 1 , wherein the compound is in the form of a pharmaceutically acceptable salt.

17. The compound of claim 1 , wherein the compound is in the form of a free base.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2020
From: THERAVANCE RESPIRATORY COMPANY, LLC
To: THERAVANCE BIOPHARMA R&D IP, LLC
Reel/Frame 054393/0695 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2014
From: THERAVANCE, INC.
To: THERAVANCE RESPIRATORY COMPANY, LLC
Reel/Frame 033371/0626 →
Continuity (4)
Continuation 1077915700 · Feb 13, 2004
Provisional Application 6046703500 · May 1, 2003
Provisional Application 6044784300 · Feb 14, 2003
Related Publication 20060223858A1 · Oct 5, 2006